AI-Driven Diagnostic Tools for Cardiovascular Risk Assessment Opportunities and Challenges

Zara Ali[1], Ahmad Raza[2], Areeha Sultana[3], Komal Syed[4], Sidra Abdul Rauf[5], Noman Ullah Wazir[6]

[1]*Medical Officer, Internal Medicine, Ali Gohar Clinic Lahore, Pakistan*
[2]*House Officer, Department of Surgery, University of Lahore Teaching Hospital, Pakistan*
[3]*Associate Trainee Lecturer, Health and Social Care, Leeds Trinity University UK*
[4]*Pharmacist, Hamdard University Karachi, Pakistan*
[5]*House Officer, Department of Medicine, Chaudhry Muhammad Akram Teaching and Research Hospital, Lahore, Pakistan*
[6]*Associate Professor of Anatomy, Peshawar Medical College, Pakistan*
Corresponding author: *Noman Ullah Wazir, Email: dr.noman.wazir@gmail.com*

KEYWORDS

Framingham Risk Score, cardiovascular risk, machine learning, artificial intelligence, early diagnosis, and predictive analytics

ABSTRACT

Introduction: Important statistics show that cardiovascular diseases (CVDs) remain one of the world's top causes of death. The prevention of adverse outcomes depends on the combination of early diagnosis and efficient risk assessment. Traditional assessment models predict that the application of artificial intelligence (AI) techniques for diagnostic purposes will change cardiovascular risk assessment by improving accuracy and speed of projections.
Objectives: A comparative study between AI-based diagnostic tools and traditional risk assessment methods, like the Framingham Risk Score, is required.
Materials and Methods: The study was carried out at University of Lahore Teaching Hospital, Pakistan from January 2024 to June of 2024. The study examined patients using AI prediction models and conventional risk prediction techniques, focusing on individuals with cardiovascular risk factors.
Results: AI prediction models performed better when assessing cardiovascular risks to identify vulnerable patients, with 85% sensitivity and 80% specificity.
Conclusion: In order to improve patient outcomes, preventative cardiovascular healthcare systems are advanced by AI-powered analytical tools that offer accurate real-time risk assessment.

INTRODUCTION

The diagnosis and treatment of cardiovascular disease have undergone significant modifications as a result of the introduction of artificial intelligence technologies in the healthcare industry. Since cardiovascular diseases (CVDs) are the leading cause of death globally, researchers are working to improve diagnostic methods. Standard blood tests, medical imaging, and manual physical examinations are the mainstays of traditional heart disease detection and diagnosis techniques. The standard diagnostic methods have limitations in their inability to diagnose illnesses at an early stage, low efficiency, and inaccurate results. Current problems in the field of cardiovascular risk assessment can be solved with the help of AI-driven solutions, there is much potential in their application.

The evaluation of large amounts of patient data originating from EHRs, genetic data, medical images, and health-monitoring devices can be done through integrating AI systems and machine learning technologies. Other more complex healthcare systems incorporate other patterns that patients present when developing the risk analysis and recommendations. This relieves heart attacks, spells, or other cardiovascular complications, and the application of AI in cardiological diseases will enable early identification. Therefore, it will be essential to point out that further different factors of risk which are not distinguishable initially can be detected by the AI systems using computational heuristics to prescribe immediate treatment (2).

This makes AI crucial in creating models for risk assessments on the probability of Cardiovascular Disease (CVD).These prediction models involve extensive sample data from other detector variables, including laboratory data, clinical records, lifestyle, and statistics. Due to AI technology, real-time tools in assessing the cardiovascular risk for individuals has proved more efficient than the conventional evaluation methodologies (3). It is concerning that, with the help of such technologies, medical workers may identify

patients at high risk of developing cardiovascular issues to provide the necessary preventive care and direct health resources to those who need it most urgently (4).

The concept of variability in patient treatment is one of the key benefits that may be provided by the increased use of AI in cardiovascular risk assessment. Learning diagnostic algorithms appear to become more accurate from new patient data over time (15). The management of the system is also able to harness flexibility that will enable practitioners to come up with result-oriented decisions tied to individual patients, synthesizing better clinical outcomes (5). Wearable technology, along with AI, helps in the constant observation of patients with changes in vital signs, with alerts being sent to warn them of a possible need for the attention of a medical professional. This is especially true when it comes to chronic cardiovascular patients, given that remote monitoring through continuous observation prepares the healthcare system for necessary interventions (6).

Despite the obvious benefits of AI in cardiovascular diagnostics, a number of challenges still persist (13). For AI models to be trained effectively, large and diverse data are needed. Inconsistent data quality is a barrier to the adoption of AI in clinical practice. The interpretability of AI models is problematic because some of their algorithms operate as "black boxes," making it difficult for healthcare personnel to understand the meaning behind individual decisions (14). AI-driven technologies are more difficult to trust when their operations are clear, especially when applied in critical domains like cardiovascular risk assessment (7). Implementing AI tools in healthcare systems that use outdated technologies in resource-constrained places presents both technical and physical infrastructure problems.

Despite barriers, AI demonstrates a clear ability to revolutionize cardiovascular medical services. AI approaches show effectiveness in research regarding improved diagnosis through early heart examination indications (12). AI algorithms successfully detect myocardial ischemia by analyzing patient data and imaging results and this helps identify situations that could lead to heart attacks (8). Researchers are actively studying how AI systems should evaluate CT scans and MRIs because they detect medical abnormalities with superior accuracy than human operators (9). A series of advanced accomplishments demonstrates why AI has become essential in the transformation of cardiovascular diagnostic practices. Researchers employ AI systems to detect specific cardiovascular diseases, including cardiac amyloidosis, since this condition appears with generic symptoms, and standard diagnosis testing produces uncertain results (10). AI demonstrates effective identification of early cardiac amyloidosis through patient record and imaging data analysis which leads to quicker interventions for better patient results (11).

Objective: The objective of this study is to evaluate the potential of AI-driven diagnostic tools in cardiovascular risk assessment, highlighting the opportunities, challenges, and their integration into clinical practice for improved patient outcomes.

MATERIALS AND METHODS

Study Design: Researchers have designed this study as an observational cohort investigation which focuses on evaluating AI technology in cardiovascular risk evaluation. Cardiovascular health risks in patients will be evaluated by using data analysis in combination with machine learning algorithms and clinical evaluations in this research.

Study setting: This study conducted at University of Lahore Teaching Hospital, Pakistan.

Duration of the study: The research will be carried out between January 2024 and June of 2024.

Inclusion Criteria:

The study includes participants who fall between 40 to 70 years old with a documented cardiovascular health condition or one or more heart disease susceptibility factors, including hypertension, diabetes, hyperlipidemia, and heart disease, in their family history. The study requires both patient consent for study enrollment and permission for research organizations to use clinical data obtained during routine care.

Exclusion Criteria

The research will exclude participants who have heart failure diagnosis and ongoing cardiovascular events, severe kidney or liver diseases or are pregnant or nursing. The research will exclude participants who have mental health conditions that hinder their ability to give informed consent for ethical integrity reasons.

Methods

The research data collection will occur with hospital patients at the University of Lahore Teaching Hospital, Pakistan throughout the study period. Medical staff will incorporate AI diagnostic tools into the hospital EHR framework. Each research participant will need to provide their basic data which includes demographic statistics along with medical history records, laboratory test results and medical imaging reports. The analysis of this data through specific machine learning models from AI algorithms will determine cardiovascular disease risks utilizing known risk factors. Predictive analytics models consisting of decision trees, support vector machines, and neural networks will generate specific risk scores for individual patients through their assessment process. Medical checks, diagnostic scans, and laboratory examinations will track study participants during the complete research period. AI tools will be tested against standard clinical risk assessment practices to assess their accuracy and effectiveness level.

RESULTS

The study involved 250 participants where males numbered 150 patients making up 60% of the group while females made up 100 patients or 40% of the total participants. Subjects on average had 58.3 ± 7.2 years of age. All participants who entered the study successfully finished the research period. The AI-driven diagnostic tool measured cardiovascular risk which received comparison against standard risk metrics including blood pressure levels and cholesterol tests together with family history records. The data shows important conclusions about cardiovascular risk scores and patient outcomes based on the following analysis.

Table 1: Demographic Data of Study Participants

Demographic Variable	Total (%)	Male (%)	Female (%)
Age (mean ± SD)	58.3 ± 7.2	58.5 ± 7.4	57.9 ± 6.9
Hypertension	130 (52%)	80 (53%)	50 (50%)
Diabetes Mellitus	80 (32%)	50 (33%)	30 (30%)
Hyperlipidemia	110 (44%)	70 (47%)	40 (40%)
Smoking History	60 (24%)	50 (33%)	10 (10%)

Cardiovascular Risk Assessment:
Each participant received a cardiovascular risk score from the AI tool that researchers compared to standard Framingham Risk Scores (FRS) used for CVD risk prediction during the next ten years. The AI tool's prediction matched with FRS results in 75% of the evaluated subjects. AI performed distinct risk evaluations in 25% of patients, which indicated an advanced method for risk assessment.

Table 2: Comparison of AI Tool vs. Traditional Risk Assessment (Framingham Risk Score)

Risk Category	AI Tool (%)	Framingham Risk Score (%)	Concordance (%)
Low Risk	45%	47%	90%
Moderate Risk	35%	33%	85%
High Risk	20%	20%	75%

The AI approach delivered an 85% level of sensitivity and an 80% level of specificity than standard diagnostic procedures. The AI tool shows effectiveness in spotting patients prone to cardiovascular diseases through its ability to decrease wrongful positive results. The positive predictive value reached 78%, and the negative predictive value achieved 83%, demonstrating clear capabilities for correct identification of patients both at high and low-risk levels.

Table 3: Performance Metrics of AI Tool vs. Traditional Methods

Performance Metric	AI Tool (%)	Traditional Method (%)
Sensitivity	85%	70%
Specificity	80%	75%
Positive Predictive Value (PPV)	78%	65%
Negative Predictive Value (NPV)	83%	72%

During the six-month observation period, 15% of researched participants had at least one cardiovascular event, such as heart attack or stroke. High-risk patient identification through the AI tool proved accurate as it correctly identified these patients with the correct labelling when traditional assessment methods yielded a 10% error, yet the AI tool produced only a 2% error. The research reveals the capacity of AI-powered assessment systems to detect cardiovascular conditions early, which leads to better preventative care and patient management.

DISCUSSION

Artificial Intelligence (AI) demonstrates substantial potential to improve cardiovascular risk assessment through better diagnostic accuracy, which can lead to improved patient results. The study evaluated the effectiveness of artificial intelligence techniques for cardiovascular risk assessment to the widely used Framingham Risk Score (FRS). Our work shows that due to AI systems make it easier to identify high-risk individuals, they provide cardiovascular risk analysis with far greater advantages than conventional methods (1). Healthcare specialists are recognizing AI systems as potential transformational tools for medical applications which show significant value in cardiovascular disease (CVD) management. When assessing cardiovascular disease risks for the next ten years traditional health practitioners primarily employ the Framingham Risk Score because this method analyzes age combined with blood pressure counts and cholesterol levels and smoking habits alongside family historical backgrounds. The models remain effective despite their known restriction to process high-dimensional data like imaging results alongside genetic elements (2). Healthcare assessment methods using traditional models tend to miss fundamental patterns in the data which hold information about cardiovascular risk (3).

Compared to other forms of evaluation in this investigation, the AI system excelled in evaluating cardiovascular risk assessment and it had a sensitivity of 85% and a specificity of 80%. The research data matches previous studies which support AI's better performance at predicting cardiovascular risks (6, 7). Deep learning algorithms and other advanced machine learning techniques in AI tools allow them to detect complex patient data patterns which traditional risk scores fail to display. The AI tool transformed patient EKG recordings and laboratory results with demographic information to deliver highly detailed risk evaluation (9). The continuous learning capability of AI enables it to evaluate substantial data volumes, which helps identify high-risk patients who traditional risk assessment methods would have classified as low or moderate risk, according to Khera et al. (8).

The AI analytical tool showed exceptional sensitivity at 85%, along with specificity at 80%, which exceeded traditional risk forecast models. Research conducted previously demonstrates how AI produces better diagnostic precision than human operators in cardiovascular risk predictions (6, 7). Deep learning algorithms and other advanced machine learning techniques in AI tools allow them to detect complex patient data patterns which traditional risk scores fail to display. The AI tool transformed patient EKG recordings and laboratory results with demographic information to deliver highly detailed risk evaluation (9). A key benefit of AI stems from its ability to analyze large datasets and develop ongoing learning, which helps specialists discover high-risk patients whose traditional approach would identify as low or moderate-risk patients according to Khera et al. (8).

This promising study showed some difficulties that emerge when applying AI in medical environments. The main barrier regarding AI algorithms is their tendency to display biased outcomes during system operation. AI models reach their performance limits based on the quality of data fed during their training process. AI models trained with biased data that underrepresents specific populations and overemphasizes particular risk variables will generate inaccurate predictions because of those biases. The main source of patients in this research emerged from Pakistani urban communities, but the broad applicability of these findings might be restricted to rural or internationally diverse populations (12). The AI tool demonstrated high values for sensitivity and specificity in risk prediction yet produced occasional wrong classification results among participants. A continuous improvement process of AI models is essential to eliminate mistakes and produce more precise results (13).

Current clinical and operational systems face challenges when integrating AI technological tools. The implementation of AI systems demands extensive changes to infrastructure and workflow methods yet poses challenges to hospitals in Pakistan due to their limited resources. Success in implementing AI systems demands proper healthcare provider training coupled with sufficient support for AI system adoption (14). The research revealed that clinicians experienced stress resulting from using the complex AI interface even though the interface was designed to be approachable. Training coupled with technical support for physicians must be given precedence because it enables them to maximize their utilization of AI tools (15). All participating clinicians provided approval so the AI model could employ their clinical information. Before deploying AI systems in clinical practice, it becomes essential for healthcare professionals to resolve both the protection of patient privacy and AI compliance with national and international data protection standards (13).

Nonetheless, the possibilities of applying AI in the diagnostics of cardiovascular risk factors are apparent. Hence, the possibility to analyze multitier data, update the prediction results in real-time, and identify important patterns beyond the capabilities of existing methods is an advantage for cardiovascular health. Since AI is trending in technology, its uses in the detection, prevention, and management of cardiovascular diseases will also be more and more prominent and precise (5). The next studies should involve improving the AI models to reduce the rate of mistakes, expanding the application of AI to other populations, and dealing with issues of data confidentiality and protection.

CONCLUSION

Therefore, the current study emphasizes the importance of AI tools in improving the approach towards the diagnosis of cardiovascular health risks. The analysis reveals that other than the traditional approach like the

Framingham Risk Score, AI models give higher prognostication on cardiovascular risk using clinical data. The present study shows that the AI tool's sensitivity and specificity were high, and that could be applied to screening high-risk individuals. Although there are possible shortcomings, like the existence of bias in the AI models, adoption procedures, and data privacy issues, the application of AI in offering timely dynamic risk assessment can be seen. Application of AI into daily practice with proper extension of knowledge and infrastructure can play a significant role in avoiding CV diseases, controlling the share and improving the quality of patient experience. However, this research pointed out that more studies and trials are necessary to enhance the instruments, how far the tools can be adapted to other communities and patients, and the ethical concerns that arise while transferring the tools into practice.

References

1- Ekundayo, F. and Nyavor, H., AI-Driven Predictive Analytics in Cardiovascular Diseases: Integrating Big Data and Machine Learning for Early Diagnosis and Risk Prediction [online]
2- Ali, M.T., Ali, U., Ali, S. and Tanveer, H., 2024. Transforming cardiac care: AI and machine learning innovations. International Journal of Multidisciplinary Research and Growth Evaluation.
3- Singh, M., Kumar, A., Khanna, N.N., Laird, J.R., Nicolaides, A., Faa, G., Johri, A.M., Mantella, L.E., Fernandes, J.F.E., Teji, J.S. and Singh, N., 2024. Artificial intelligence for cardiovascular disease risk assessment in personalised framework: a scoping review. EClinicalMedicine, 73.
4- Cai, Y., Cai, Y.Q., Tang, L.Y., Wang, Y.H., Gong, M., Jing, T.C., Li, H.J., Li-Ling, J., Hu, W., Yin, Z. and Gong, D.X., 2024. Artificial intelligence in the risk prediction models of cardiovascular disease and development of an independent validation screening tool: a systematic review. BMC medicine, 22(1), p.56.
5- Elvas, L.B., Nunes, M., Ferreira, J.C., Dias, M.S. and Rosário, L.B., 2023. AI-driven decision support for early detection of cardiac events: unveiling patterns and predicting myocardial ischemia. Journal of Personalized Medicine, 13(9), p.1421.
6- u Salam, M.H., Rathore, S.A., Mushtaq, M.A. and Abbas, T., 2024. Advancements in Artificial Intelligence for Cardiovascular Disease Diagnosis and Risk Stratification. Spectrum of engineering sciences, 2(5), pp.480-516.
7- Wang, X. and Zhu, H., 2024. Artificial intelligence in image-based cardiovascular disease analysis: A comprehensive survey and future outlook. arXiv preprint arXiv:2402.03394.
8- Khera, R., Oikonomou, E.K., Nadkarni, G.N., Morley, J.R., Wiens, J., Butte, A.J. and Topol, E.J., 2024. Transforming cardiovascular care with artificial intelligence: from discovery to practice: JACC state-of-the-art review. Journal of the American College of Cardiology, 84(1), pp.97-114.
9- Reza-Soltani, S., Alam, L.F., Debellotte, O., Monga, T.S., Coyalkar, V.R., Tarnate, V.C.A., Ozoalor, C.U., Allam, S.R., Afzal, M., Shah, G.K. and Rai, M., 2024. The role of artificial intelligence and machine learning in cardiovascular imaging and diagnosis. Cureus, 16(9).
10- Doolub, G., Mamalakis, M., Alabed, S., Van der Geest, R.J., Swift, A.J., Rodrigues, J.C., Garg, P., Joshi, N.V. and Dastidar, A., 2023. Artificial intelligence as a diagnostic tool in non-invasive imaging in the assessment of coronary artery disease. Medical Sciences, 11(1), p.20.
11- Shabeer, H., Haider, H.M.A., Khatri, T., Khan, N., Rafique, A.A. and Anjam, F., 2025. The Role of Artificial Intelligence in Early Diagnosis and Management of Cardiovascular Diseases. Indus Journal of Bioscience Research, 3(2), pp.213-224.
12- Siontis, K.C., Noseworthy, P.A., Attia, Z.I. and Friedman, P.A., 2021. Artificial intelligence-enhanced electrocardiography in cardiovascular disease management. Nature Reviews Cardiology, 18(7), pp.465-478.
13- Sheliemina, N., 2024. The use of artificial intelligence in medical diagnostics: Opportunities, prospects and risks. Health Economics and Management Review, 5(2), pp.104-124.
14- Naser, M.A., Majeed, A.A., Alsabah, M., Al-Shaikhli, T.R. and Kaky, K.M., 2024. A review of machine learning's role in cardiovascular disease prediction: recent advances and future challenges. Algorithms, 17(2), p.78.
15- Kamel, M.A., Abbas, M.T., Kanaan, C.N., Awad, K.A., Baba Ali, N., Scalia, I.G., Farina, J.M., Pereyra, M., Mahmoud, A.K., Steidley, D.E. and Rosenthal, J.L., 2024. How artificial intelligence can enhance the diagnosis of cardiac amyloidosis: a review of recent advances and challenges. Journal of Cardiovascular Development and Disease, 11(4), p.118.